Full-year results showed an adjusted net loss of £3.2m, some £1.3m better than forecast, with year-end cash of £5.3m and sufficient to more than cover the cost of the ongoing Phase IIa study of SNG001 in COPD patients. Although the enrolment rate is slower than we had hoped, due to the mild start to the respiratory virus season, we are hugely reassured by the fact that all patients enrolled are virus-positive, which increases the probability of SNG001 (inhaled interferon-bet
25 Feb 2019
Synairgen - Finals – Phase II patient selection as good as it gets
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Synairgen - Finals – Phase II patient selection as good as it gets
Synairgen plc (SNG:LON) | 6.8 0 2.3% | Mkt Cap: 13.6m
- Published:
25 Feb 2019 -
Author:
Mark Brewer -
Pages:
7
Full-year results showed an adjusted net loss of £3.2m, some £1.3m better than forecast, with year-end cash of £5.3m and sufficient to more than cover the cost of the ongoing Phase IIa study of SNG001 in COPD patients. Although the enrolment rate is slower than we had hoped, due to the mild start to the respiratory virus season, we are hugely reassured by the fact that all patients enrolled are virus-positive, which increases the probability of SNG001 (inhaled interferon-bet